Evidence map›Paper›PMID 27507643›Full record

ArticleCytotechnology2016

Promoting differentiation of cultured myoblasts using biomimetic surfaces that present alpha-laminin-2 peptides.

Francine Parker, Kathryn White, Siȏn Phillips, Michelle Peckham

Open access · hybridAbstract read
In one paragraph

Article in Cytotechnology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Francine ParkerSchool of Molecular and Cellular Biology, Faculty of Biological Sciences, The University of Leeds, Leeds, LS2 9JT, UK.
Kathryn WhiteSchool of Molecular and Cellular Biology, Faculty of Biological Sciences, The University of Leeds, Leeds, LS2 9JT, UK.
Siȏn PhillipsBioscience Centre, International Centre for Life, Orla Protein Technologies Ltd, Newcastle upon Tyne, NE1 4EP, UK.
Michelle PeckhamSchool of Molecular and Cellular Biology, Faculty of Biological Sciences, The University of Leeds, Leeds, LS2 9JT, UK. m.peckham@leeds.ac.uk.ORCID http://orcid.org/0000-0002-3754-2028
University of Leeds · GBCentre for Life · GB

Funding

Medical Research Council MR/K001272/1
6 · The paper itself

Abstract

Traditionally, muscle cell lines are cultured on glass coverslips and differentiated to investigate myoblast fusion and differentiation. Efficient differentiation of myoblasts produces a dense network of myotubes with the correct organisation for contraction. Here we have tested the ability of artificially generated, precisely controlled peptide surfaces to enhance the efficiency of myoblast differentiation. We focused on specific short peptides from α-laminin-2 (IKVSV, VQLRNGFPYFSY and GLLFYMARINHA) as well as residues 15-155 from FGF1. We tested if these peptides in isolation, and/or in combination promoted muscle differentiation in culture, by promoting fusion and/or by improving sarcomere organisation. The majority of these peptides promoted fusion and differentiation in two different mouse myogenic cell lines and in primary human myoblasts. The additive effects of all four peptides gave the best results for both mouse cell lines tested, while primary human cell cultures differentiated equally well on most peptide surfaces tested. These data show that a mixture of short biomimetic peptides can reliably promote differentiation in mouse and human myoblasts.

Indexed as

DifferentiationLAMA2LamininMyoblastMyogenesisPeptides

Identifiers

PMID27507643
PMCPMC5023573
OpenAlexW2507632269

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.